# Kilitch Drugs India Ltd (KILITCH)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹185.18
Day Change: +1.6%
52W High: ₹250
52W Low: ₹117.25
Market Cap: ₹610 Cr

## Valuation
P/E: 22.24
P/B: 2.16
EPS: ₹7.84
Book Value: ₹80.61
Dividend Yield: 0%

## Returns
1Y Return: -0.97%

## Profitability
ROE: 12.36%
ROCE: 17.18%
Debt/Equity: 0.32
Revenue Growth: 47.2%
Profit Growth: 26.5%
EBITDA Margin: 19.39%
Operating Margin: 24.04%

## About
Kilitch Drugs India Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Kilitch Drugs India Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Announcement: Board Meeting Outcome for Submission Of Audited Standalone And Consolidated Financial Results For The Quarter Ended 31St March, 2026
- Announcement: Audited Standalone And Consolidated Financial Results For The Quarter Ended 31St March, 2026
- BSE Filing: Board Meeting Outcome for Submission Of Audited Standalone And Consolidated Financial Results For The Quarter Ended 31St March, 2026

## Access
Current tier: anonymous
More history: Register free to see 12 more years.

## Data Freshness
Quote Updated: 2026-05-25T20:00:13.927Z
Price History Updated: 2026-05-25T05:33:28.019Z
Latest Price History Date: 2026-05-24
Technicals Updated: 2026-05-25T05:33:28.019Z
Quant Updated: 2026-05-25T05:33:28.019Z
Sentiment Updated: 2026-05-25T05:33:28.019Z
Financials Status: current
Financials Updated: 2026-05-19T13:30:53.443Z
Financials Last Attempt: 2026-05-19T13:30:53.443Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (FY25)
Revenue: ₹197.24 Cr
Operating Profit: ₹28.63 Cr (OPM 14.52%)
Net Profit: ₹26.7 Cr
Tax: ₹9.53 Cr

## Annual P&L History
FY25: Rev ₹197.24Cr | PAT ₹26.7Cr | OPM 14.52%
FY24: Rev ₹153.61Cr | PAT ₹14.6Cr | OPM 13.72%
FY23: Rev ₹138.86Cr | PAT ₹10.45Cr | OPM 10.33%

## Balance Sheet (FY25)
Total Assets: ₹312.78 Cr
Total Liabilities: ₹112.33 Cr
Borrowings: ₹49.42 Cr
Cash: ₹9.75 Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Mukund Prataprai Mehta B.Com., LL.B., Executive Chairman & MD
- Mira Bhavin Mehta, MD & Director
- Bhavin Mukund Mehta B.Pharm., Whole-time Director
- Sunil Sureshji Jain, Chief Financial Officer
- Tajouddin  Ansari, VP-Marketing & Operation

---
Source: rupiya.io/stocks/kilitch
Disclaimer: For research and education only. Not investment advice.